TY - JOUR
T1 - Effects of Tacrolimus and Other Immune Targeting Compounds on Binge-Like Ethanol Drinking in High Drinking in the Dark Mice
AU - Grigsby, Kolter B.
AU - Savarese, Antonia M.
AU - Metten, Pamela
AU - Mason, Barbara J.
AU - Blednov, Yuri A.
AU - Crabbe, John C.
AU - Ozburn, Angela R.
N1 - Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Supported by NIH grants AA013519, AA010760, AA020245, T32 AA07468, F32 AA027692, U01AA025476, and US Department of Veterans Affairs Grants BX000313 and IK2 BX002488, and a gift from the John R. Andrews Family.
Publisher Copyright:
© The Author(s) 2020.
PY - 2020
Y1 - 2020
N2 - High Drinking in the Dark (HDID-1) mice represent a unique genetic risk model of binge-like drinking and a novel means of screening potential pharmacotherapies to treat alcohol use disorders (AUDs). We tested the effects of tacrolimus (0, 0.5, 1, and 2 mg/kg), sirolimus (0, 5, 10, and 20 mg/kg), palmitoylethanolamide (PEA; 0, 75, 150, and 225 mg/kg), and secukinumab (0, 5, 20, and 60 mg/kg) on binge-like ethanol intake (2-day, “Drinking in the Dark” [DID]) and blood alcohol levels (BALs) in HDID-1 mice. Tacrolimus reduced ethanol intake and BALs. Tacrolimus had no effect on water intake, but reduced saccharin intake. There was no effect of sirolimus, PEA, or secukinumab on ethanol intake or BALs. These results compare and contrast with previous work addressing these compounds or their targeted mechanisms of action on ethanol drinking, highlighting the importance of screening a wide range of models and genotypes to inform the role of neuroimmune signaling in AUDs.
AB - High Drinking in the Dark (HDID-1) mice represent a unique genetic risk model of binge-like drinking and a novel means of screening potential pharmacotherapies to treat alcohol use disorders (AUDs). We tested the effects of tacrolimus (0, 0.5, 1, and 2 mg/kg), sirolimus (0, 5, 10, and 20 mg/kg), palmitoylethanolamide (PEA; 0, 75, 150, and 225 mg/kg), and secukinumab (0, 5, 20, and 60 mg/kg) on binge-like ethanol intake (2-day, “Drinking in the Dark” [DID]) and blood alcohol levels (BALs) in HDID-1 mice. Tacrolimus reduced ethanol intake and BALs. Tacrolimus had no effect on water intake, but reduced saccharin intake. There was no effect of sirolimus, PEA, or secukinumab on ethanol intake or BALs. These results compare and contrast with previous work addressing these compounds or their targeted mechanisms of action on ethanol drinking, highlighting the importance of screening a wide range of models and genotypes to inform the role of neuroimmune signaling in AUDs.
KW - Binge drinking
KW - HDID-1
KW - immune
KW - pharmacotherapy
UR - http://www.scopus.com/inward/record.url?scp=85096767672&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85096767672&partnerID=8YFLogxK
U2 - 10.1177/2633105520975412
DO - 10.1177/2633105520975412
M3 - Article
AN - SCOPUS:85096767672
SN - 2633-1055
VL - 15
JO - Neuroscience Insights
JF - Neuroscience Insights
ER -